Table 1.
Clinical Characteristics
| Characteristic | HIV-Negative Control | HIV+/Untreated | HIV+/ART-Treated/Sup | P Value (HIV+/Untreated vs HIV+/ART-Treated Sup) |
|---|---|---|---|---|
| Total No. of subjects | 16 | 32 | 27 | |
| Age, y | 54 (37–62) | 49 (35–55) | 42 (36–53) | |
| CD4+ T-cell count, cells/μL | 799 (690–914) | 255 (98–490) | 570 (500–670) | <.0001 |
| Plasma HIV RNA load, log10 copies/mL | … | 4.9 (4.3–5.5) | 1.3 (1.3-1.3) | <.0001 |
| CSF HIV RNA load, log10 copies/mL | … | 3.9 (2.9–5.1) | 1.3 (1.3-1.3) | <.0001 |
| CSF WBCs, cells/uL | 1.5 (1.0–2.8) | 10 (1.5–19) | 0 (0–2.0) | <.0001 |
| BBB permeability, ratio | 4.65 (3.9–6.6) | 6.3 (4.5–7.3) | 4.9 (3.5–5.8) | .004 |
| QNZP4, score | –0.06 (–0.42 to 0.45) | –0.4 (–2.85 to 0.16) | 0.29 (–0.31 to 0.88) |
Data are presented as median (interquartile range) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; BBB, blood-brain barrier; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; HIV+, human immunodeficiency virus infected; QNZP4, global cognition score.